[1] Infectious Diseases Cooperative Group, Gynecology and Obstetrics Branch, Chinese Medical Association. Guidelines for antibiotic use in obstetrics and gynecology[J]. Chin J Obstet Gynecol(中华妇产科杂志), 2011, 3(46):230-233.
[2] IORIO A, SPENCER F A, FALAVIGNA M, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients[J]. BMJ, 2015, 350:h870.
[3] BALSHWM H,HELFANDA M,SCHUNEMANN H J, et al. GRADE Guidelines: 3. Rating the Quality of Evidence[J]. Chin J Evid Base Med (中国循证医学杂志), 2011, 6(4):451-455.
[4] Working Group on the revision of the Guidelines for Clinical Application of Antimicrobial Therapy. Guidelines for Clinical Application of Antimicrobial Therapy (抗菌药物临床应用指导原则)[M]. Beijing: People's Medical Publishing House, 2015.
[5] Ministry of Health of the People'ASIs Republic of China. No. 84, Ministry of Health on revising the home page of inpatient medical records[EB/OL]. National Health Commission of the People's Republic of China, 2011 [2020-05-08]. http://www.nhc.gov.cn/zwgk/wtwj/201304/47b4226ff93c4800bab61c045ddb6642.shtml?tdsourcetag=s_pctim_aiomsg.
[6] SiChuan Pharmacy Administration and Quality Control Center. Implementation Rules of Perioperative Prophylactic Application of Antibiotics in Sichuan Province(四川省围手术期预防性应用抗菌药物实施细则)[EB/OL]. SiChuan Pharmacy Administration and Quality Control Center, 2019 [2020-05-08]. http://jkzx.cd120.com/newsPage.jspx?mcid=36.
[7] BEN SHOHAM A, BAR-MEIR M, IOSCOVICH A, et al. Timing of antibiotic prophylaxis in cesarean section: retrospective, difference-in-differences estimation of the effect on surgical-site-infection[J]. J Matern Fetal Neonatal Med, 2019, 32(5):804-808.
[8] ZHANG C, ZHANG L, LIU X, et al. Timing of antibiotic prophylaxis in elective caesarean delivery: a multi-center randomized controlled trial and Meta-analysis[J]. PLoS One, 2015, 10(7):e0129434.
[9] SI J G. The humble opinion on the guiding principles for clinical application of antimicrobial therapy[J]. Chin J Hosp Pharm (中国医院药学杂志), 2016, 36(12):1031-1033.
[10] GYTE G M, DOU LVAZQUEZ J C. Different classes of antibiotics given to women routinely for preventing infection at caesarean section[J/OR]. Cochrane Database of Systematic Reviews, 2014, 11 [2020-05-08]. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008726.pub2/full.
[11] American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery[J]. Obstet Gynecol, 2018, 132(3):e103-e119.
[12] SMAILL F M, GRIVELL R M. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section[J/OR]. Cochrane Database of Systematic Reviews, 2014, 10 [2020-05-08]. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007482.pub3/full.
[13] TITA A T N, SZYCHOWSKI J M, BOGGESS K, et al. Adjunctive azithromycin prophylaxis for cesarean delivery[J]. New Engl J Med, 2016, 375(13):1231-1241.
[14] HARPER L M, KILGORE M, SZYCHOWSKI J M, et al. Economic evaluation of adjunctive azithromycin prophylaxis for cesarean delivery[J]. Obstet Gynecol, 2017, 130(2):328-334.
[15] GILBERT D N, CHAMBERS H F, ELIOPOULOS G M, et al. The Sanford Guide to Antimicrobial Therapy(热病) [M]. Beijing: Peking Union Medical College Press, 2018.
[16] ACHILLES S L, REEVES M F. Prevention of infection after induced abortion[J]. Contraception, 2011, 83(4):295-309.
[17] COSTESCU DGUILBERTÉ. No. 360-Induced Abortion: Surgical Abortion and Second Trimester Medical Methods[J]. J Obstet Gynaecol Canada, 2018, 40(6):750-783.
[18] American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 195: Prevention of infection after gynecologic procedures[J]. Obstet Gynecol, 2018, 131(6):e172-e189.
[19] American College of Obstetricians and Gynecologists. Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin Summary, Number 225[J]. Obstet Gynecol, 2020, 136(4):855-858.
[20] LEVALLOIS P, RIOUX J E. Prophylactic antibiotics for suction curettage abortion: results of a clinical controlled trial[J]. Am J Obstet Gynecol, 1988, 158(1):100-105.
[21] YAO Y, MA X X, LI J K, et al. Application of prophylactic doxycycline in different crowd in perioperative period of induced abortion [J]. Prog Mod Biomed (现代生物医学进展), 2016, 16(25):4938-4940.
[22] HEINEMANN J, GILLEN G, SANCHEZ-RAMOS L, et al. Do mechanical methods of cervical ripening increase infectious morbidity? A systematic review[J]. Am J Obstet Gynecol, 2008, 199(2):177-188.
[23] MACKEEN A D, DURIE D E, LIN M, et al. Foley plus oxytocin compared with oxytocin for induction after membrane rupture: a randomized controlled trial[J]. Obstet Gynecol, 2018, 131(1):4-11.
[24] STOCK L, BASHAM E, GOSSETT D R, et al. Factors associated with wound complications in women with obstetric anal sphincter injuries (OASIS)[J]. Am J Obstet Gynecol, 2013, 208(4):327.e1-327.e6.
[25] ROTEM R, MASTROLIA S A, ROTTENSTREICH M, et al. The use of metronidazole in women undergoing obstetric anal sphincter injuries: a systematic review of the literature[J]. Arch Gynecol Obstet, 2020, 1:20.
[26] DUGGAL N, MERCADO C, DANIELS K, et al. Antibiotic prophylaxis for prevention of postpartum perineal wound complications: a randomized controlled trial[J]. Obstet Gynecol, 2008, 111(6):1268-1273.
[27] MLLER B R, ALLEN J, TOFT B, et al. Pelvic inflammatory disease after hysterosalpingography associated with Chlamydia trachomatis and Mycoplasma hominis[J]. Int J Obstet Gynaecol, 1984, 91(12):1181-1187.
[28] LI H M, SUNG F C, LI S C, et al. The effect of antibiotic prophylaxis for acute pelvic inflammatory disease after hysterosalpingography: a retrospective cohort study[J]. Curr Med Res Opin, 2018, 34(7):1271-1276.
[29] PEREIRA N, HUTCHINSON A P, LEKOVICH J P, et al. Antibiotic prophylaxis for gynecologic procedures prior to and during the utilization of assisted reproductive technologies: a systematic review[J]. J Pathog, 2016, 2016: 4698314.
[30] Reproductive Health, World Health Organization. Selected practice recommendations for contraceptive use [EB/OL]. World Health Organization, 2016 [2020-05-08]. https://www.who.int/reproductivehealth/publications/family_planning/SPR-3/en/.
[31] Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit. Intrauterine Contraception[EB/OL]. FSRH guidance, [2020-05-08]. https://www.fsrh.org/standards-and-guidance/documents/ceuguidanceintrauterinecontraception/.
[32] GRIMES D A, LOPEZ L MSCHULZ K F. Antibiotic prophylaxis for intrauterine contraceptive device insertion[EB/OL]. Cochrane database of systematic reviews, [2020-05-08]. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001327/full.
[33] World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children) [EB/OL]. World Health Organization. 2019 [2020-05-08]. https://www.who.int/medicines/publications/essentialmeds_committeereports/en/.